Federated Hermes Inc. Acquires Shares of 153,494 Revvity, Inc. (NYSE:RVTY)

Federated Hermes Inc. bought a new position in Revvity, Inc. (NYSE:RVTY) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 153,494 shares of the company’s stock, valued at approximately $16,778,000. Federated Hermes Inc. owned approximately 0.12% of Revvity as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in RVTY. Gladius Capital Management LP grew its stake in Revvity by 84.1% in the third quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after purchasing an additional 106 shares during the period. CENTRAL TRUST Co purchased a new stake in shares of Revvity in the 4th quarter worth about $27,000. ORG Partners LLC bought a new position in shares of Revvity in the 4th quarter worth about $32,000. JTC Employer Solutions Trustee Ltd bought a new position in shares of Revvity in the 4th quarter worth about $33,000. Finally, Desjardins Global Asset Management Inc. purchased a new position in Revvity during the 4th quarter valued at about $37,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Stock Down 0.1 %

Revvity stock opened at $100.77 on Tuesday. Revvity, Inc. has a one year low of $79.50 and a one year high of $135.67. The stock has a fifty day moving average of $104.69 and a 200 day moving average of $101.52. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.77 and a current ratio of 2.07. The stock has a market cap of $12.45 billion, a PE ratio of 18.32, a price-to-earnings-growth ratio of 2.63 and a beta of 1.09.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The firm had revenue of $695.90 million during the quarter. As a group, sell-side analysts predict that Revvity, Inc. will post 4.65 EPS for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Friday, April 19th will be given a $0.07 dividend. The ex-dividend date is Thursday, April 18th. This represents a $0.28 annualized dividend and a yield of 0.28%. Revvity’s payout ratio is presently 5.09%.

Insider Transactions at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on RVTY. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and raised their target price for the company from $88.00 to $125.00 in a research note on Thursday, January 4th. KeyCorp raised their price objective on Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Raymond James boosted their target price on Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Barclays upped their price target on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. Finally, Stifel Nicolaus lifted their target price on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.91.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.